Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

fiercebiotech.com

FierceBiotech

Get the latest updates from FierceBiotech directly as they happen.

Follow now 312 followers

Latest posts

Last updated about 2 hours ago

Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech

about 2 hours ago

Having already stripped back their development plans for the estrogen receptor (ER)...

QL Biopharm links once-monthly GLP-1 to incumbent-rivaling weight loss in phase 2

about 2 hours ago

Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1...

Leader of NIH's intramural research program to depart agency

about 2 hours ago

The director of internal research at the National Institutes of Health is...

Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug

about 4 hours ago

Roche dived into the metabolic dysfunction-associated steatohepatitis space by agreeing to hand...

ArsenalBio lays off 50% of staff in pivot from early-stage research

about 16 hours ago

One of the top fundraisers of 2024 is halving its workforce about...

Dexcom CEO goes on leave while Insulet taps new CFO

about 21 hours ago

The changes at the diabetes tech companies include Dexcom announcing that outgoing...

VC Aditum launches cardiovascular biotech, offers Mabwell up to $1B for siRNA asset

about 23 hours ago

California VC firm Aditum Bio is at it again, this time partnering...

J&J's IL-23 drug defeats reigning champ Sotyktu in phase 3 psoriasis trial

about 23 hours ago

After being touted as a potential rival to Bristol Myers Squibb’s reigning...

Regeneron reports phase 3 win in ultra-rare disease, bouncing back to spark race to FDA

about 24 hours ago

Regeneron is racing to regulators after reporting a phase 3 win in...

Lilly rounds out oral GLP-1 weight loss data, posts semaglutide-topping results in diabetes

1 day ago

At this year’s meeting of the European Association for the Study of...

Why Sanofi's R&D chief is 'pretty pragmatic' about a 'mixed' year of clinical development

1 day ago

Sanofi’s head of R&D, Houman Ashrafian, Ph.D., spoke to Fierce days before...